Literature DB >> 19300871

Interpreting biomarker data in therapeutic trials.

P S Aisen1.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19300871     DOI: 10.1007/s12603-009-0034-9

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  10 in total

1.  A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

Authors:  P S Aisen; K L Davis; J D Berg; K Schafer; K Campbell; R G Thomas; M F Weiner; M R Farlow; M Sano; M Grundman; L J Thal
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

2.  Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.

Authors:  Richard K Gordon; Julian R Haigh; Gregory E Garcia; Shawn R Feaster; Michael A Riel; David E Lenz; Paul S Aisen; Bhupendra P Doctor
Journal:  Chem Biol Interact       Date:  2005-10-26       Impact factor: 5.192

3.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

Authors:  M J de Leon; S DeSanti; R Zinkowski; P D Mehta; D Pratico; S Segal; H Rusinek; J Li; W Tsui; L A Saint Louis; C M Clark; C Tarshish; Y Li; L Lair; E Javier; K Rich; P Lesbre; L Mosconi; B Reisberg; M Sadowski; J F DeBernadis; D J Kerkman; H Hampel; L-O Wahlund; P Davies
Journal:  Neurobiol Aging       Date:  2005-08-26       Impact factor: 4.673

4.  Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.

Authors:  Francine Gervais; Julie Paquette; Céline Morissette; Pascale Krzywkowski; Mathilde Yu; Mounia Azzi; Diane Lacombe; Xianqi Kong; Ahmed Aman; Julie Laurin; Walter A Szarek; Patrick Tremblay
Journal:  Neurobiol Aging       Date:  2006-05-03       Impact factor: 4.673

5.  A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

Authors:  P S Aisen; D Saumier; R Briand; J Laurin; F Gervais; P Tremblay; D Garceau
Journal:  Neurology       Date:  2006-11-02       Impact factor: 9.910

6.  Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Authors:  Lisa Mosconi; Wai H Tsui; Karl Herholz; Alberto Pupi; Alexander Drzezga; Giovanni Lucignani; Eric M Reiman; Vjera Holthoff; Elke Kalbe; Sandro Sorbi; Janine Diehl-Schmid; Robert Perneczky; Francesca Clerici; Richard Caselli; Bettina Beuthien-Baumann; Alexander Kurz; Satoshi Minoshima; Mony J de Leon
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

7.  A pilot study of prednisone in Alzheimer's disease.

Authors:  P S Aisen; D Marin; L Altstiel; C Goodwin; B Baruch; R Jacobson; T Ryan; K L Davis
Journal:  Dementia       Date:  1996 Jul-Aug

Review 8.  Imaging biomarkers and their role in dementia clinical trials.

Authors:  Howard Chertkow; Sandra Black
Journal:  Can J Neurol Sci       Date:  2007-03       Impact factor: 2.104

Review 9.  Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Authors:  Harald Hampel; Katharina Bürger; Stefan J Teipel; Arun L W Bokde; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

10.  Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Authors:  N C Fox; R S Black; S Gilman; M N Rossor; S G Griffith; L Jenkins; M Koller
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

  10 in total
  2 in total

1.  Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Authors:  M W Weiner
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

2.  Use of biomarkers in Alzheimer's trials.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.